Azomyr

Country: Европска Унија

Језик: Енглески

Извор: EMA (European Medicines Agency)

Купи Сада

Активни састојак:

desloratadine

Доступно од:

N.V. Organon

АТЦ код:

R06AX27

INN (Међународно име):

desloratadine

Терапеутска група:

Antihistamines for systemic use,

Терапеутска област:

Rhinitis, Allergic, Perennial; Urticaria; Rhinitis, Allergic, Seasonal

Терапеутске индикације:

Azomyr is indicated for the relief of symptoms associated with:allergic rhinitis (see section 5.1)urticaria (see section 5.1)

Резиме производа:

Revision: 52

Статус ауторизације:

Authorised

Датум одобрења:

2001-01-15

Информативни летак

                                30
B. PACKAGE LEAFLET
31
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
AZOMYR 5 MG FILM-COATED TABLETS
desloratadine
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, pharmacist or
nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible
side effects not listed in this leaflet.
See section 4.
WHAT IS IN THIS LEAFLET
1.
What Azomyr is and what it is used for
2.
What you need to know before you take Azomyr
3.
How to take Azomyr
4.
Possible side effects
5.
How to store Azomyr
6.
Contents of the pack and other information
1.
WHAT AZOMYR IS AND WHAT IT IS USED FOR
WHAT AZOMYR IS
Azomyr contains desloratadine which is an antihistamine.
HOW AZOMYR WORKS
Azomyr is an antiallergy medicine that does not make you drowsy. It
helps control your allergic
reaction and its symptoms.
WHEN AZOMYR SHOULD BE USED
Azomyr relieves symptoms associated with allergic rhinitis
(inflammation of the nasal passages
caused by an allergy, for example, hay fever or allergy to dust mites)
in adults and adolescents
12 years of age and older. These symptoms include sneezing, runny or
itchy nose, itchy palate, and
itchy, red or watery eyes.
Azomyr is also used to relieve the symptoms associated with urticaria
(a skin condition caused by an
allergy). These symptoms include itching and hives.
Relief of these symptoms lasts a full day and helps you to resume your
normal daily activities and
sleep.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE AZOMYR
DO NOT TAKE AZOMYR
-
if you are allergic to desloratadine, or any of the other ingredients
of this medicine (listed in
section 6) or to loratadine.
WARNINGS AND PRECAUTIONS
Talk to your doctor, pharmacist or nurse before taking Azomyr:
-

                                
                                Прочитајте комплетан документ
                                
                            

Карактеристике производа

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Azomyr 5 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 5 mg desloratadine.
Excipient(s) with known effect
This medicinal product contains lactose (see section 4.4).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablets
Light blue, round and embossed film-coated tablets with elongated
letters “S” and “P” on one side and
plain on the other. The diameter of the film-coated tablet is 6.5 mm.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Azomyr is indicated in adults and adolescents aged 12 years and older
for the relief of symptoms
associated with:
-
allergic rhinitis (see section 5.1)
-
urticaria (see section 5.1)
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_Adults and adolescents (12 years of age and over) _
The recommended dose of Azomyr is one tablet once a day.
Intermittent allergic rhinitis (presence of symptoms for less than 4
days per week or for less than
4 weeks) should be managed in accordance with the evaluation of
patient’s disease history and the
treatment could be discontinued after symptoms are resolved and
reinitiated upon their reappearance.
In persistent allergic rhinitis (presence of symptoms for 4 days or
more per week and for more than
4 weeks), continued treatment may be proposed to the patients during
the allergen exposure periods.
_Paediatric population _
There is limited clinical trial efficacy experience with the use of
desloratadine in adolescents
12 through 17 years of age (see sections 4.8 and 5.1).
The safety and efficacy of Azomyr 5 mg film-coated tablets in children
below the age of 12 years have
not been established.
Method of administration
Oral use.
The dose can be taken with or without food.
3
4.3
CONTRAINDICATIONS
Hypersensitivity to the active substance, to any of the excipients
listed in section 6.1, or to loratadine.
4.4
SPECIAL WARNINGS AND PRECAUTIONS FOR USE
Renal function impairment
In the ca
                                
                                Прочитајте комплетан документ
                                
                            

Документи на другим језицима

Информативни летак Информативни летак Бугарски 02-08-2023
Информативни летак Информативни летак Шпански 02-08-2023
Информативни летак Информативни летак Чешки 02-08-2023
Информативни летак Информативни летак Дански 02-08-2023
Информативни летак Информативни летак Немачки 02-08-2023
Информативни летак Информативни летак Естонски 02-08-2023
Информативни летак Информативни летак Грчки 02-08-2023
Информативни летак Информативни летак Француски 02-08-2023
Карактеристике производа Карактеристике производа Француски 02-08-2023
Информативни летак Информативни летак Италијански 02-08-2023
Карактеристике производа Карактеристике производа Италијански 02-08-2023
Извештај о процени јавности Извештај о процени јавности Италијански 07-07-2015
Информативни летак Информативни летак Летонски 02-08-2023
Информативни летак Информативни летак Литвански 02-08-2023
Карактеристике производа Карактеристике производа Литвански 02-08-2023
Информативни летак Информативни летак Мађарски 02-08-2023
Информативни летак Информативни летак Мелтешки 02-08-2023
Информативни летак Информативни летак Холандски 02-08-2023
Карактеристике производа Карактеристике производа Холандски 02-08-2023
Информативни летак Информативни летак Пољски 02-08-2023
Информативни летак Информативни летак Португалски 02-08-2023
Карактеристике производа Карактеристике производа Португалски 02-08-2023
Извештај о процени јавности Извештај о процени јавности Португалски 07-07-2015
Информативни летак Информативни летак Румунски 02-08-2023
Информативни летак Информативни летак Словачки 02-08-2023
Информативни летак Информативни летак Словеначки 02-08-2023
Карактеристике производа Карактеристике производа Словеначки 02-08-2023
Извештај о процени јавности Извештај о процени јавности Словеначки 07-07-2015
Информативни летак Информативни летак Фински 02-08-2023
Информативни летак Информативни летак Шведски 02-08-2023
Информативни летак Информативни летак Норвешки 02-08-2023
Информативни летак Информативни летак Исландски 02-08-2023
Карактеристике производа Карактеристике производа Исландски 02-08-2023
Информативни летак Информативни летак Хрватски 02-08-2023

Обавештења о претрази у вези са овим производом

Погледајте историју докумената